BMS Accuses Teva Of Infringing Eliquis Blood Thinner Patent
By Bonnie Eslinger (February 16, 2021, 6:36 PM GMT) -- A Bristol-Myers Squibb subsidiary has fought back against Teva Pharmaceuticals' bid to invalidate the European patent for its blockbuster blood thinner, rejecting the generic drugmaker's claim that it did little more than write down the formula for a previously discovered anticoagulant.
In its defense filed with the High Court, the Bristol-Myers Squibb unit maintained that its patent for the key compound in its branded drug Eliquis makes "an important and plausible technical contribution to the art."
Bristol-Myers Squibb Holdings Ireland Unlimited Co. also lobbed counterclaims against Teva on Thursday, seeking a declaration that the generic drugmaker would be infringing its patent...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!